引用(参考)文献：真性赤血球増加症、本態性血小板血症と血栓症（6）
血栓症の治療：真性赤血球増加症、本態性血小板血症（5）から続く
真性赤血球増加症（真性多血症：PV）、本態性血小板血症（ET）と血栓症関連の記事をシリーズでお届けしてきましたが、最後に、最近発表された重要な論文の引用をつけておきたいと思います。
原則としてここ数年以内の新しい論文を中心に紹介させていただきます（ただし、特に重要な論文では、例外もあります）。
なお、番号はこれまでの記事で本文中にふってきた番号と一致させています。
【文献】
1) Passamonti F, Brusamolino E, Bernasconi C, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica. 2000; 85:1011-8.
2) Marchioli R, Finazzi G, Barbui T, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005; 23: 2224-32.
3) Gangat N, Strand J, Tefferi A, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007; 138: 354-8.
4) Chim CS, Kwong YL, Liang R, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005; 165: 2651-8.
5) Jensen MK, de Nully Brown P, Hasselbalch HC, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000; 65: 132-9.
6) Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366: 1945-53.
7) Carobbio A, Finazzi G, Barbui T, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007; 109: 2310-3.
8) De Stefano V, Za T, Rossi E, Vannucchi AM, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008; 93: 372-80.
9) Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008; 22: 2020-8.
10) Chait Y, Condat B, Brière JB. et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005; 129: 553-60.
11) Brière JB. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost. 2006; 32: 208-18.
12) Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006; 107: 4214-22.
13) Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science. 1980; 207(4430): 541-3.
14) Wautier MP, El Nemer W, Wautier JL, et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood. 2007; 110: 894-901.
15) Michiels JJ, Berneman Z, Schroyens W, et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006; 32: 174-207.
16) Cortelazzo S, Finazzi G, Barbui T, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995; 332: 1132-6.
17) Colaizzo D, Amitrano L, Margaglione M, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007; 5: 55-61.
18) Boissinot M, Lippert E, Hermouet S, et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood. 2006; 108: 3223-4.
19) Primignani M, Barosi G, Mannucci PM, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006; 44: 1528-34.
20) Patel RK, Lea NC, Mufti GJ, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006; 130: 2031-8.
21) De Stefano V, Fiorini A, Leone G, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007; 5: 708-14.
22) Kiladjian JJ, Cervantes F, Valla DC, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008; 111: 4922-9.
23) Pardanani A, Lasho TL, Tefferi A, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc. 2008; 83: 457-9.
24) Arellano-Rodrigo E, Alvarez-Larrán A, Cervantes F, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006; 91: 169-75.
25) Falanga A, Marchetti M, Barbui T, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol. 2007; 35: 702-11.
26) Carobbio A, Finazzi G, Barbui T, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008; 112: 3135-7.
27) Marchetti M, Castoldi E, Falanga A, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008; 112: 4061-8.
28) Sozer S, Fiel MI, Hoffman R, et al. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009; 113: 5246-9.
29) Santilli F, Romano M, Davì G. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood. 2008; 112: 1085-90.
30) Harrison CN, Campbell PJ, Green AR, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353: 33-45.
31) Maugeri N, Giordano G, Donati MB, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost. 2006; 4: 2593-8.
32) Landolfi R, Marchioli R, Barbui T, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004; 350: 114-24.
33) Ruggeri M, Rodeghiero F, Barbui T, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008; 111: 666-71.
（続く） 本態性血小板血症／真性赤血球増加症：血栓症（インデックス）へ
【凝固検査＆DIC】
１）血液凝固検査入門
２）DIC（図解）
３）DIC（治療ほか）
【関連記事】
金沢大学第三内科HPへ
金沢大学第三内科ブログへ
研修医・入局者募集へ
研修医の広場（金沢大学第三内科） ← 当科での研修の様子をご覧いただくことができます。
投稿者：血液内科・呼吸器内科at 06:32| 血栓性疾患 | コメント(0)